Loading news...
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market opportunity remains robust.
BOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced the appointment of Vanessa Jacoby, Chief Business and Financial Officer of Quanta Therapeutics, Inc., to its Board of Directors and to serve as Chair of its Audit Committee. Sonoma also announced the retirement of its longtime director, Dr. Jay Birnbaum.
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) insider Teresa Mccarthy sold 2,929 shares of the business's stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $72.45, for a total transaction of $212,206.05. Following the sale, the insider owned 113,938 shares of the company's stock, valued at
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) insider Steven George Hughes sold 4,895 shares of the business's stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $72.45, for a total transaction of $354,642.75. Following the completion of the transaction, the insider owned 31,599 shares
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) CFO Michael Maclean sold 4,542 shares of the firm's stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $72.45, for a total value of $329,067.90. Following the transaction, the chief financial officer owned 59,290 shares of the
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) insider W. Michael Flanagan sold 6,534 shares of Avidity Biosciences stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $72.45, for a total transaction of $473,388.30. Following the sale, the insider directly owned 85,093 shares in the
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate R&D, betting on new modeling tools and automated labs to unlock efficiency gains across their pipeline.
Shares of Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) have earned a consensus recommendation of "Hold" from the twenty-three brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, fourteen have assigned a hold recommendation and eight have given a buy recommendation to
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) insider W. Michael Flanagan sold 2,373 shares of Avidity Biosciences stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $72.23, for a total transaction of $171,401.79. Following the sale, the insider directly owned 91,627 shares of the company's stock,
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) CFO Michael Maclean sold 1,974 shares of the stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $72.23, for a total value of $142,582.02. Following the sale, the chief financial officer directly owned 63,832 shares in the
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) insider Steven George Hughes sold 2,373 shares of the business's stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $72.23, for a total transaction of $171,401.79. Following the completion of the sale, the insider owned 36,494 shares in the
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) insider John Moriarty sold 2,374 shares of the business's stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $72.23, for a total transaction of $171,474.02. Following the completion of the sale, the insider owned 74,557 shares in the company,
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) insider Charles Calderaro III sold 3,727 shares of the firm's stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $72.23, for a total value of $269,201.21. Following the sale, the insider directly owned 49,797 shares of the company's stock,
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) CEO Sarah Boyce sold 8,576 shares of the company's stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $72.23, for a total transaction of $619,444.48. Following the transaction, the chief executive officer owned 283,394 shares of the company's stock,
Avidity Biosciences, Inc. (NASDAQ: RNA - Get Free Report) crossed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $71.20 and traded as high as $72.15. Avidity Biosciences shares last traded at $72.07, with a volume of 4,664,241 shares. Wall Street Analysts Forecast Growth A
Avidity Biosciences (NASDAQ: RNA - Get Free Report) and Galecto (NASDAQ: GLTO - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk. Risk and Volatility Avidity Biosciences has a beta of
The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday. The sector has bounced back since. However, small biotech stocks have been on a huge run since mid-September, due primarily to a notable uptick in M&A activity across the industry. Numerous small and midcap biotech/biopharma stocks have been purchased for significant buyout premiums in recent months.
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
SAN DIEGO , Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its Managed Access Program (MAP) for investigational therapy delpacibart zotadirsen (del-zota) for eligible people with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44) in the United States. "We recognize the considerable needs facing the DMD44 community given there are no approved exon skipping therapies for this disease as well as the potential of del-zota based on the unprecedented data shown in our clinical studies," said Sarah Boyce, President and Chief Executive Officer of Avidity.
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $0.65 per share a year ago.